Aquestive Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with a $4,600 or more in losses are are encouraged to contact the firm before April 30, 2021; click here to submit trade information

LOS ANGELES, April 28, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Aquestive Therapeutics, Inc. (NASDAQ: AQST) investors that acquired shares between December 2, 2019 and September 25, 2020. Investors have until April 30, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this complaint that Aquestive made misleading and false statements to the market. Data was included in Aquestive’s New Drug Application submission for Libervant Buccal Film for the management of seizure clusters, showing a suboptimal drug exposure level as applied to certain weight groups. The likelihood of the NDA achieving approval was lowered by this inappropriate data. Aquestive’s public statements were false and materially misleading throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Aquestive.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar

Attorney Advertising

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.